Boosting defenses: can extra vaccine doses protect vulnerable patients?
NCT ID NCT03069703
Summary
This study tested whether giving stronger or extra doses of pneumonia vaccines could better protect patients with a rare autoimmune disease (ANCA-associated vasculitis) who are taking a drug called rituximab. Rituximab weakens the immune system, making these patients more prone to severe infections. Researchers compared the standard two-shot vaccine schedule against two more intense schedules to see which one triggered a better protective immune response and was safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE PNEUMOCOCCAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pôle de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques " Hôpital Cochin, Assistance Publique-Hôpitaux de Paris
Paris, Paris, 75014, France
Conditions
Explore the condition pages connected to this study.